GlassScriptPhysician profile
Kimberly Fordham
NPI 1881127173
$916.08
in general payments reported to CMS, 2019-2025
24 companies · $84.46 in 2025
The $84.46 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.12 · 2020: $14.53 · 2021: $33.73 · 2022: $76.09 · 2023: $292 · 2024: $373 · 2025: $84.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $222.91 | 2019-2024 | Andexxa, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.50 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $66.67 | 2022-2023 | Xarelto |
| Aimmune Therapeutics, INC. | $33.46 | 2024 | |
| Kyowa Kirin, INC. | $28.00 | 2024 | Crysvita |
| Paratek Pharmaceuticals, INC. | $27.55 | 2023-2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $26.19 | 2023 | |
| Abbvie INC. | $24.44 | 2025 | |
| Boston Scientific Corporation | $23.37 | 2023 | Watchman Access System |
| Exact Sciences Corporation | $23.13 | 2024 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $22.56 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $21.81 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.37 | 2023 | |
| Alnylam Pharmaceuticals INC. | $20.97 | 2023 | Givlaari |
| Chiesi USA, INC. | $20.30 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.20 | 2024 | |
| Edwards Lifesciences Corporation | $17.66 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Vertex Pharmaceuticals Incorporated | $17.27 | 2024 | |
| Gilead Sciences, INC. | $16.66 | 2023 | Veklury |
| Glaxosmithkline, LLC. | $15.67 | 2022 | |
| Pharming Healthcare, INC. | $15.37 | 2023 | Ruconest |
| Genentech USA, INC. | $14.53 | 2020 | |
| Amgen INC. | $14.47 | 2024 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $14.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Fordham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.